BioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 230,800 Shares

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 230,800 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00.

BioSyent Price Performance

RX stock opened at C$11.70 on Tuesday. BioSyent Inc. has a 52 week low of C$8.24 and a 52 week high of C$11.74. The firm has a market capitalization of C$135.60 million, a P/E ratio of 19.50 and a beta of 0.93. The company has a fifty day simple moving average of C$11.05 and a two-hundred day simple moving average of C$10.27. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19.

BioSyent (CVE:RX) last announced its quarterly earnings results on Monday, August 26th. The company reported C$0.13 EPS for the quarter, meeting analysts’ consensus estimates of C$0.13. The firm had revenue of C$8.95 million during the quarter, compared to the consensus estimate of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. Analysts anticipate that BioSyent Inc. will post 0.6944444 earnings per share for the current fiscal year.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.